@article{MTMT:34768269,
	title = {Electroretinographical Analysis of the Effect of BGP-15 in Eyedrops for Compensating Global Ischemia–Reperfusion in the Eyes of Sprague Dawley Rats},
	url = {https://m2.mtmt.hu/api/publication/34768269},
	author = {Takács, Barbara and Szilágyi, Anna and Priksz, Dániel and Bombicz, Mariann and Szabó, Adrienn Mónika and Pelles-Taskó, Beáta and Rusznyák, Ágnes and Haimhoffer, Ádám and Gesztelyi, Rudolf and Szilvássy, Zoltán and Juhász, Béla and Varga, Balázs},
	doi = {10.3390/biomedicines12030637},
	journal-iso = {BIOMEDICINES},
	journal = {BIOMEDICINES},
	volume = {12},
	unique-id = {34768269},
	abstract = {Retinal vascular diseases and consequential metabolic disturbances in the eye are major concerns for healthcare systems all around the world. BGP-15, a drug candidate small-molecule [O-(3-piperidino-2-hydroxy-1-propyl) nicotinic amidoxime dihydrochloride], has been formerly demonstrated by our workgroup to be retinoprotective both in the short and long term. Based on these results, the present study was performed to investigate the efficacy of BGP in an eyedrop formulation containing sulfobutylether-β-cyclodextrin (SBECD), which is a solubility enhancer as well. Electroretinographical evaluations were carried out and BGP was demonstrated to improve both scotopic and photopic retinal a- and b-waves, shorten their implicit times and restore oscillatory potentials after ischemia–reperfusion. It was also observed to counteract retinal thinning after ischemia–reperfusion in the eyes of Sprague Dawley rats. This small-molecule drug candidate is able to compensate for experimental global eye ischemia–reperfusion injury elicited by ligation of blood vessels in rats. We successfully demonstrated that BGP is able to exert its protective effects on the retina even if administered in the form of eyedrops.},
	year = {2024},
	eissn = {2227-9059},
	pages = {637},
	orcid-numbers = {Priksz, Dániel/0000-0002-5818-4557; Rusznyák, Ágnes/0000-0002-8837-7499; Haimhoffer, Ádám/0000-0003-2123-5821; Gesztelyi, Rudolf/0000-0001-7911-055X}
}

@article{MTMT:34763932,
	title = {Assessing the Impact of Influenza Vaccination Timing on Experimental Arthritis : Effects on Disease Progression and Inflammatory Biomarkers},
	url = {https://m2.mtmt.hu/api/publication/34763932},
	author = {Tarjányi, Vera and Ménes, Ákos and Hamid, Leila and Kurucz, Andrea and Priksz, Dániel and Varga, Balázs and Gesztelyi, Rudolf and Kiss, Rita and Horváth, Ádám István and Szentes, Nikolett and Helyes, Zsuzsanna and Szilvássy, Zoltán and Bombicz, Mariann},
	doi = {10.3390/ijms25063292},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {25},
	unique-id = {34763932},
	issn = {1661-6596},
	abstract = {Numerous studies have indicated a link between vaccines and the exacerbation of autoimmune diseases including rheumatoid arthritis (RA). However, there is no consensus in clinical practice regarding the optimal timing of immunization. Therefore, this study aimed to investigate the impact of the 3Fluart influenza vaccine on the complete Freund's adjuvant (CFA)-induced chronic arthritis rat model and to identify new biomarkers with clinical utility. CFA was injected into the plantar surface of one hind paw and the root of the tail on day 0, and the tail root injection was repeated on day 1. Flu vaccination was performed on day 1 or 7. Paw volume was measured by plethysmometry, mechanonociceptive threshold by dynamic plantar aesthesiometry, neutrophil myeloperoxidase (MPO) activity, and vascular leakage using in vivo optical imaging throughout the 21-day experiment. Inflammatory markers were determined by Western blot and histopathology. CFA-induced swelling, an increase in MPO activity, plasma extravasation in the tibiotarsal joint. Mechanical hyperalgesia of the hind paw was observed 3 days after the injection, which gradually decreased. Co-administration of the flu vaccine on day 7 but not on day 1 resulted in significantly increased heme oxygenase 1 (HO-1) expression. The influenza vaccination appears to have a limited impact on the progression and severity of the inflammatory response and associated pain. Nevertheless, delayed vaccination could alter the disease activity, as indicated by the findings from assessments of edema and inflammatory biomarkers. HO-1 may serve as a potential marker for the severity of inflammation, particularly in the case of delayed vaccination. However, further investigation is needed to fully understand the regulation and role of HO-1, a task that falls outside the scope of the current study.},
	keywords = {Inflammation; Reactive oxygen species; Autoimmunity; vaccination; Heme Oxygenase-1; INFLUENZA; Adjuvant effect; complete Freund’s adjuvant-induced; neutrophil myeloperoxidase activity; vaccine-mediated autoimmunity},
	year = {2024},
	eissn = {1422-0067},
	orcid-numbers = {Gesztelyi, Rudolf/0000-0001-7911-055X}
}

@article{MTMT:34400338,
	title = {A kardiális miozinaktivátorok klinikai alkalmazhatósága a preklinikai vizsgálatok tükrében [= Clinical applications of cardiac myosin activators in the light of preclinical studies]},
	url = {https://m2.mtmt.hu/api/publication/34400338},
	author = {Ráduly, Arnold Péter and Sárkány, Fruzsina and Kovács, Máté Balázs and Juhász, Béla and Horváth, Balázs and Szentandrássy, Norbert and Nánási, Péter Pál and Édes, István and Csanádi, Zoltán and Tóth, Attila and Papp, Zoltán and Priksz, Dániel and Borbély, Attila},
	doi = {10.26430/CHUNGARICA.2023.53.5.476},
	journal-iso = {CARDIOL HUNG},
	journal = {CARDIOLOGIA HUNGARICA},
	volume = {53},
	unique-id = {34400338},
	issn = {0133-5596},
	abstract = {A csökkent ejekciós frakciójú szívelégtelenség (HFrEF) gyógyszeres kezelésében az utóbbi évtizedben jelentős fejlődés következett be. A kórkép patomechanizmusának középpontjában álló kontraktilis diszfunkciót direkten javító, úgynevezett pozitív inotróp szerek azonban továbbra sem hoztak átütő sikert. Az ideális pozitív inotróp szer nem fokozza a myocardium energiaigényét és oxigénfelhasználását. Az eddig használt gyógyszerek sajnos maradéktalanul nem tudtak megfelelni ezeknek az elvárásoknak. Az aktin-miozin-interakció direkt modulálása miozinaktivátorokkal egy új terápiás célpont a kontrakciós erő fokozására, a korábbi szerekre jellemző káros mellékhatások nélkül. Klinikai vizsgálatokban az első ilyen gyógyszer, az omecamtiv-mecarbil (OM) – a III. fázis vizsgálatok kezdeti pozitív eredményei ellenére – megfelelő hatékonyság hiánya miatt mégsem került bevezetésre a klinikai gyakorlatba. Ezen vegyület alkalmazhatóságát korlátozó tényezőket számos preklinikai tanulmány vizsgálta. Az OM sikertelensége ugyanakkor egy új típusú miozinaktivátor, a danicamtiv kifejlesztését is potencírozta. A danicamtivval kapcsolatos preklinikai és klinikai vizsgálatok jelenleg még korlátozott számban érhetőek el. Az eddigi eredmények biztatóbbak a danicamtivval kapcsolatban, azonban ennek megerősítésére még számos vizsgálatra van szükség. Feltételezhetően mindkét gyógyszerjelölt jövőbeli alkalmazhatóságát diasztolés diszfunkciót okozó hatásuk korlátozhatja.
		
		Summary:
		There have been significant advances in the management of heart failure with reduced ejection fraction (HFrEF) over the last decade. However, the so-called positive inotropic agents, which directly correct the contractile dysfunction at the heart of the pathomechanism of the disease, have still not been a resounding success. The ideal positive inotropic agent does not increase myocardial energy demand and oxygen consumption. Unfortunately, the drugs used so far have not fully met these requirements. Direct modulation of the actin-myosin interaction by myosin activators is a new therapeutic target to enhance contractile force without the adverse side effects typical of previous agents. In clinical trials, the first such drug, omecamtiv mecarbil (OM), has not been introduced into clinical practice due to lack of adequate efficacy, despite initial positive results in phase III trials. Several preclinical studies have investigated the limiting factors for the applicability of this compound. However, the failure of OM has also stimulated the development of a new type of myosin activator, danicamtiv. Preclinical and clinical studies on danicamtiv are currently limited. The results to date are more encouraging for danicamtiv, but many more studies are needed to confirm this. Presumably, the future applicability of both candidates may be limited by their adverse effects on diastolic function.},
	keywords = {Myosin activators; Danicamtiv; omecamtiv-mecarbil; pozitív inotrópia; diasztolés diszfunkció; positive inotropy; miozinaktivátor; diastolic dyfunction},
	year = {2023},
	eissn = {1588-0230},
	pages = {476-483},
	orcid-numbers = {Horváth, Balázs/0000-0003-2562-8446; Szentandrássy, Norbert/0000-0003-0197-9567}
}

@article{MTMT:34394226,
	title = {A Microsurgical Arteriovenous Malformation Model on Saphenous Vessels in the Rat},
	url = {https://m2.mtmt.hu/api/publication/34394226},
	author = {Al-Smadi, Mohammad and Fazekas, László Ádám and Aslan, Siran and Bernát, Brigitta Renáta and Beqain, Anas and Al-Khafaji, Mustafa Qais Muhsin and Priksz, Dániel and Orlik, Brigitta and Németh, Norbert},
	doi = {10.3390/biomedicines11112970},
	journal-iso = {BIOMEDICINES},
	journal = {BIOMEDICINES},
	volume = {11},
	unique-id = {34394226},
	abstract = {Arteriovenous malformation (AVM) is an anomaly of blood vessel formation. Numerous models have been established to understand the nature of AVM. These models have limitations in terms of the diameter of the vessels used and the impact on the circulatory system. Our goal was to establish an AVM model that does not cause prompt and significant hemodynamic and cardiac alterations but is feasible for follow-up of the AVM’s progression. Sixteen female rats were randomly divided into sham-operated and AVM groups. In the AVM group, the saphenous vein and artery were interconnected using microsurgical techniques. The animals were followed up for 12 weeks. Anastomosis patency and the structural and hemodynamic changes of the heart were monitored. The hearts and vessels were histologically analyzed. During the follow-up period, shunts remained unobstructed. Systolic, diastolic, mean arterial pressure, and heart rate values slightly and non-significantly decreased in the AVM group. Echocardiogram results indicated minor systolic function impact, with slight and insignificant changes in aortic pressure and blood velocity, and minimal left ventricular wall enlargement. The small-caliber saphenous AVM model does not cause acute hemodynamic changes. Moderate but progressive alterations and venous dilatation confirmed AVM-like features. The model seems to be suitable for studying further the progression, enlargement, or destabilization of AVM.},
	year = {2023},
	eissn = {2227-9059},
	pages = {2970},
	orcid-numbers = {Aslan, Siran/0009-0007-4352-4102; Bernát, Brigitta Renáta/0000-0001-6090-1001; Németh, Norbert/0000-0002-1162-3778}
}

@article{MTMT:34126717,
	title = {Therapeutic Aspects of Prunus cerasus Extract in a Rabbit Model of Atherosclerosis-Associated Diastolic Dysfunction},
	url = {https://m2.mtmt.hu/api/publication/34126717},
	author = {Szekeres, Réka Mária and Priksz, Dániel and Kiss, Rita and Romanescu, Dana Diana and Bombicz, Mariann and Varga, Balázs and Gesztelyi, Rudolf and Szilágyi, Anna and Takács, Barbara and Tarjányi, Vera and Pelles-Tasko, Beata and Forgács, Ildikó Noémi and Gálné Remenyik, Judit and Szilvássy, Zoltán and Juhász, Béla},
	doi = {10.3390/ijms241713253},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {24},
	unique-id = {34126717},
	issn = {1661-6596},
	abstract = {This study evaluates the potential therapeutic effects of anthocyanin-rich Prunus cerasus (sour cherry) extract (PCE) on atherosclerosis-associated cardiac dysfunction, described by the impairment of the NO-PKG (nitric oxide–protein kinase G) pathway and the antioxidant capacity. Initially, a rabbit model of atherosclerotic cardiovascular disease was established by administering a cholesterol-rich diet, enabling the examination of the impact of 9 g/kg PCE on the pre-existing compromised cardiovascular condition. After that, the animals were divided into four groups for 12 weeks: the (1) untreated control group; (2) PCE-administered healthy rabbits; (3) hypercholesterolemic (HC) group kept on an atherogenic diet; and (4) PCE-treated HC group. Dyslipidemia, impaired endothelial function, and signs of diastolic dysfunction were evident in hypercholesterolemic rabbits, accompanied by a reduced cardiac expression of eNOS (endothelial nitric oxide synthase), PKG, and SERCA2a (sarco/endoplasmic reticulum calcium ATPase 2a). Subsequent PCE treatment improved the lipid profile and the cardiac function. Additionally, PCE administration was associated with elevated myocardial levels of eNOS, PKG, and SERCA2a, while no significant changes in the vascular status were observed. Western blot analysis further revealed hypercholesterolemia-induced increase and PCE-associated reduction in heme oxygenase-1 expression. The observed effects of anthocyanins indicate their potential as a valuable addition to the treatment regimen for atherosclerosis-associated cardiac dysfunction.},
	year = {2023},
	eissn = {1422-0067},
	orcid-numbers = {Kiss, Rita/0000-0003-1208-366X; Romanescu, Dana Diana/0000-0002-6002-8975; Gesztelyi, Rudolf/0000-0001-7911-055X}
}

@article{MTMT:33856409,
	title = {Paclitaxel Protects against Isoproterenol-Induced Damage in Rat Myocardium: Its Heme-Oxygenase Mediated Role in Cardiovascular Research},
	url = {https://m2.mtmt.hu/api/publication/33856409},
	author = {Matusovits, Danica and Murlasits, Zsolt and Kupai, Krisztina and Baráth, Zoltán Lajos and Hsu, Linkang and Osváth, Péter and Szűcs, Miklós and Priksz, Dániel and Juhász, Béla and Radák, Zsolt and Várkonyi, Tamás and Pávó, Imre and Pósa, Anikó},
	doi = {10.3390/antiox12051129},
	journal-iso = {ANTIOXIDANTS-BASEL},
	journal = {ANTIOXIDANTS},
	volume = {12},
	unique-id = {33856409},
	abstract = {(1) Background: In cardiovascular applications, paclitaxel inhibits smooth muscle cell proliferation and migration and significantly reduces the occurrence of restenosis and target lesion revascularization. However, the cellular effects of paclitaxel in the myocardium are not well understood; (2) Methods: Wistar rats were divided into four groups: control (CTRL), isoproterenol (ISO) treated (1 mg/kg) and two groups treated with paclitaxel (PAC), which was administrated (10 mg/kg/day) for 5 days by gavage/per os alone or in combination (ISO + PAC) 3 weeks after ISO treatment. Ventricular tissue was harvested 24 h later for measurements of heme oxygenase (HO-1), reduced glutathione (GSH), oxidized glutathione (GSSG), superoxide dismutase (SOD), NF-κB, TNF-α and myeloperoxidase (MPO); (3) Results: HO-1 protein concentration, HO-1 activity, SOD protein concentration and total glutathione significantly decreased in response to ISO treatment. When PAC was administered in conjunction with ISO, HO-1, SOD concentration and total glutathione were not different from control levels. MPO activity, NF-κB concentration and TNF-α protein concentration were significantly increased in the ISO-only group, while the levels of these molecules were restored when PAC was co-administered; (4) Conclusions: Oral administration of PAC can maintain the expression of important antioxidants, anti-inflammatory molecules, HO-1, SOD and GSH, and suppress the production of TNF-α, MPO and NF-κB, which are involved in myocardial damage. The principal component of this cellular defense seems to be the expression of HO-1.},
	year = {2023},
	eissn = {2076-3921},
	orcid-numbers = {Murlasits, Zsolt/0000-0003-4101-3417; Kupai, Krisztina/0000-0002-0644-1718; Baráth, Zoltán Lajos/0000-0003-0636-6313; Hsu, Linkang/0009-0001-2220-1562; Szűcs, Miklós/0000-0002-8606-996X; Radák, Zsolt/0000-0003-1297-6804; Várkonyi, Tamás/0000-0001-6833-3563; Pósa, Anikó/0000-0003-2167-2888}
}

@article{MTMT:33703433,
	title = {Drug Candidate BGP-15 Prevents Isoproterenol-Induced Arrhythmias and Alters Heart Rate Variability (HRV) in Telemetry-Implanted Rats},
	url = {https://m2.mtmt.hu/api/publication/33703433},
	author = {Bernát, Brigitta Renáta and Erdelyi, Rita and Fazekas, László Ádám and Garami, Greta and Szekeres, Réka Mária and Takács, Barbara and Bombicz, Mariann and Varga, Balázs and Sárkány, Fruzsina and Ráduly, Arnold and Romanescu, Dana Diana and Papp, Zoltán and Tóth, Attila and Szilvássy, Zoltán and Juhász, Béla and Priksz, Dániel},
	doi = {10.3390/ph16030359},
	journal-iso = {PHARMACEUTICALS-BASE},
	journal = {PHARMACEUTICALS},
	volume = {16},
	unique-id = {33703433},
	abstract = {Multi-target drug candidate BGP-15 has shown cardioprotective and antiarrhythmic actions in diseased models. Here, we investigated the effects of BGP-15 on ECG and echocardiographic parameters, heart rate variability (HRV), and arrhythmia incidence in telemetry-implanted rats, under beta-adrenergic stimulation by isoproterenol (ISO). In total, 40 rats were implanted with radiotelemetry transmitters. First, dose escalation studies (40–160 mg/kg BGP-15), ECG parameters, and 24 h HRV parameters were assessed. After, rats were divided into Control, Control+BGP-15, ISO, and ISO+BGP-15 subgroups for 2 weeks. ECG recordings were obtained from conscious rats, arrhythmias and HRV parameters were assessed, and echocardiography was carried out. ISO-BGP-15 interaction was also evaluated on an isolated canine cardiomyocyte model. BGP-15 had no observable effects on the ECG waveforms; however, it decreased heart rate. HRV monitoring showed that BGP-15 increased RMSSD, SD1, and HF% parameters. BGP-15 failed to counteract 1 mg/kg ISO-induced tachycardia, but diminished the ECG of ischemia and suppressed ventricular arrhythmia incidence. Under echocardiography, after low-dose ISO injection, BGP-15 administration lowered HR and atrial velocities, and increased end-diastolic volume and ventricle relaxation, but did not counteract the positive inotropic effects of ISO. Two weeks of BGP-15 treatment also improved diastolic function in ISO-treated rats. In isolated cardiomyocytes, BGP-15 prevented 100 nM ISO-induced aftercontractions. Here, we show that BGP-15 increases vagally mediated HRV, reduces arrhythmogenesis, enhances left ventricle relaxation, and suppresses the aftercontractions of cardiomyocytes. As the drug is well tolerated, it may have a clinical value in preventing fatal arrhythmias.},
	keywords = {Echocardiography; Arrhythmia; telemetry; BGP-15; heart rate variability (HRV); isoproterenol (ISO)},
	year = {2023},
	eissn = {1424-8247},
	orcid-numbers = {Bernát, Brigitta Renáta/0000-0001-6090-1001; Romanescu, Dana Diana/0000-0002-6002-8975}
}

@article{MTMT:33560204,
	title = {Examination of Preferences for COVID-19 Vaccines in Hungary Based on Their Properties—Examining the Impact of Pandemic Awareness with a Hybrid Choice Approach},
	url = {https://m2.mtmt.hu/api/publication/33560204},
	author = {Blaga, Zsanett and Czine, Péter and Takács, Barbara and Szilagyi, Anna and Szekeres, Réka Mária and Juhászné Wachal, Zita Eszter and Hegedus, Csaba and Buchholcz, Gyula and Varga, Balázs and Priksz, Dániel and Bombicz, Mariann and Vargáné Szabó, Adrienn Mónika and Kiss, Rita and Gesztelyi, Rudolf and Romanescu, Dana Diana and Szabó, Zoltán and Szűcs, Miklós and Balogh, Péter and Szilvássy, Zoltán and Juhász, Béla},
	doi = {10.3390/ijerph20021270},
	journal-iso = {INT J ENV RES PUB HE},
	journal = {INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH},
	volume = {20},
	unique-id = {33560204},
	issn = {1661-7827},
	abstract = {The COVID-19 pandemic has posed a huge challenge to the world in recent years. The development of vaccines that are as effective as possible and accessible to society offers a promising alternative for addressing the problems caused by this situation as soon as possible and to restore the pre-epidemic system. The present study investigated the preferences of residents in Hungary’s second-largest city (Debrecen) for the COVID-19 vaccine. To achieve this aim, a discrete choice experiment was conducted with 1011 participants, and the vaccine characteristics included in the design of the experiment were determined by qualitative methods and a pilot survey: (1) country of origin; (2) efficiency; (3) side effect; and (4) duration of protection. During the data collection at three vaccination sites, respondents were asked to choose between three vaccine alternatives and one “no choice” option in eight decision situations. Discrete choice model estimations were performed using a random parameter logit (RPL) specification with the final model extended to include a latent variable measuring pandemic awareness. The results showed that the vaccine with a Chinese country of origin is the least preferred among the respondents, while the Hungarian and the European vaccines are the most preferred. Furthermore, the increase in the vaccine efficiency level increased the respondents’ sense of utility for the vaccine; the short-term side effect was preferred to the long-term one; and the increase in the duration of protection provided by the vaccine increased the respondents’ sense of utility for the vaccine. Based on the parameter estimated for the latent variable, it can be concluded that as the level of pandemic awareness (which is more positive among people with chronic diseases and less important among health workers) increases, the choice of a vaccine option becomes more preferred among respondents compared to the “no choice“. The results of our investigation could contribute towards increasing compliance in the case of the vaccination-rejecting population, not only for COVID-19, but for any kind of vaccination procedure.},
	year = {2023},
	eissn = {1660-4601},
	orcid-numbers = {Kiss, Rita/0000-0003-1208-366X; Gesztelyi, Rudolf/0000-0001-7911-055X; Romanescu, Dana Diana/0000-0002-6002-8975; Szűcs, Miklós/0000-0002-8606-996X; Balogh, Péter/0000-0002-8611-0221}
}

@article{MTMT:33547730,
	title = {The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo. Implications for Clinical Applications},
	url = {https://m2.mtmt.hu/api/publication/33547730},
	author = {Ráduly, Arnold and Sárkány, Fruzsina and Kovács, Máté Balázs and Bernát, Brigitta Renáta and Juhász, Béla and Szilvássy, Zoltán and Pórszász, Róbert and Horváth, Balázs and Szentandrássy, Norbert and Nánási, Péter Pál and Csanádi, Zoltán and Édes, István and Tóth, Attila and Papp, Zoltán and Priksz, Dániel and Borbély, Attila},
	doi = {10.3390/ijms24010446},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {24},
	unique-id = {33547730},
	issn = {1661-6596},
	abstract = {Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second direct myosin activator, has achieved encouraging results in preclinical and clinical studies, thus implicating its potential applicability in the treatment of heart failure with reduced ejection fraction (HFrEF). Here, we analyzed the inotropic effects of danicamtiv in detail. To this end, changes in sarcomere length and intracellular Ca2+ levels were monitored in parallel, in enzymatically isolated canine cardiomyocytes, and detailed echocardiographic examinations were performed in anesthetized rats in the absence or presence of danicamtiv. The systolic and diastolic sarcomere lengths decreased; contraction and relaxation kinetics slowed down with increasing danicamtiv concentrations without changes in intracellular Ca2+ transients in vitro. Danicamtiv evoked remarkable increases in left ventricular ejection fraction and fractional shortening, also reflected by changes in systolic strain. Nevertheless, the systolic ejection time was significantly prolonged, the ratio of diastolic to systolic duration was reduced, and signs of diastolic dysfunction were also observed upon danicamtiv treatment in vivo. Taken together, danicamtiv improves cardiac systolic function, but it can also limit diastolic performance, especially at high drug concentrations.},
	keywords = {STRAIN; diastolic dysfunction; Myosin activators; heart failure with reduced ejection fraction; Danicamtiv; positive inotropy},
	year = {2023},
	eissn = {1422-0067},
	orcid-numbers = {Bernát, Brigitta Renáta/0000-0001-6090-1001; Horváth, Balázs/0000-0003-2562-8446; Szentandrássy, Norbert/0000-0003-0197-9567}
}

@article{MTMT:33571706,
	title = {Corrigendum: Improved survival and retinal function of aging ZDF rats in long-term, uncontrolled diabetes by BGP-15 treatment, (Front. Pharmacol, (2021), 12, (650207), 10.3389/fphar.2021.650207)},
	url = {https://m2.mtmt.hu/api/publication/33571706},
	author = {Juhászné Wachal, Zita Eszter and Szilágyi, Anna and Takács, Barbara and Vargáné Szabó, Adrienn Mónika and Priksz, Dániel and Bombicz, Mariann and Szilvássy, Judit and Juhász, Béla and Szilvássy, Zoltán and Varga, Balázs},
	doi = {10.3389/fphar.2022.1034389},
	journal-iso = {FRONT PHARMACOL},
	journal = {FRONTIERS IN PHARMACOLOGY},
	volume = {13},
	unique-id = {33571706},
	abstract = {In the published article, there was an error in affiliation 1. Instead of “Department of Pharmacology and Pharmacotherapy, University of Debrecen, Debrecen, Hungary”, it should be “Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, Debrecen, Hungary”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. © 2022 Wachal, Szilágyi, Takács, Szabó, Priksz, Bombicz, Szilvássy, Juhász, Szilvássy and Varga.},
	keywords = {SURVIVAL; Diabetes; erratum; retinopathy; BGP-15; ERG; ZDF},
	year = {2022},
	eissn = {1663-9812}
}